Shares of IDEXX Laboratories IDXX were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share increased 36.29% over the past year to $1.69, which beat the estimate of $1.42.
Revenue of $721,789,000 rose by 19.24% year over year, which beat the estimate of $669,450,000.
Outlook
IDEXX Laboratories hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Oct 29, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/wmvg5y3j
Price Action
Company's 52-week high was at $444.96
52-week low: $168.65
Price action over last quarter: Up 7.88%
Company Overview
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 38% of its revenue from outside the United States.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.